PROCEPT BioRobotics (PRCT) Cost of Revenue (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Cost of Revenue data on file, last reported at $29.2 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $29.2 million, up 16.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.0 million (up 24.89% YoY), and the FY2025 annual result was $111.8 million, up 27.95% from the prior year.
• Cost of Revenue slipped to $29.2 million in Q1 2026 per PRCT's latest filing, from $30.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $30.1 million in Q4 2025 and troughed at $6.5 million in Q1 2022.
• A 5-year average of $19.5 million and a median of $21.5 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue surged 133.03% in 2022, then gained 10.02% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $13.1 million in 2022, then jumped by 70.41% to $22.3 million in 2023, then rose by 10.02% to $24.6 million in 2024, then advanced by 22.41% to $30.1 million in 2025, then retreated by 2.94% to $29.2 million in 2026.
• Business Quant data shows PRCT's Cost of Revenue at $29.2 million in Q1 2026, $30.1 million in Q4 2025, and $29.3 million in Q3 2025.